Back to search
FDAFDA · Food and drugs·Recall number D-0910-2016

LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL

Published June 8, 2016 · Recall initiated: March 31, 2016

Summary

FDA records drug Class II recall D-0910-2016, published June 8, 2016 and initiated March 31, 2016. Recalling firm: Invisiblu International LLC; Status: Ongoing; Reported quantity: 3,319 bottles; Lot: Lot # 21511166, Exp 11/18. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Invisiblu International LLC
Distributor
Nationwide and Brazil.
Lot
Lot # 21511166, Exp 11/18
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was LGD-Xtreme (ligandrol LGD-4033),capsules, 3 mg, 90-count bottle, Manufactured for Continuum Labs, Fort Lauderdale, FL recalled?

Yes. FDA published recall D-0910-2016 on June 8, 2016. Reported hazard: Marketed Without An Approved NDA/ANDA: Contains an unapproved drug, ligandrol LGD-4033

What should I do if I have this product?

Voluntary: Firm initiated · Press Release